Published in Gene Ther on March 06, 2008
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev (2010) 1.46
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med (2012) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009) 1.41
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2011) 1.19
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther (2015) 1.06
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer (2011) 1.04
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs (2012) 1.02
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Reovirus: a targeted therapeutic--progress and potential. Mol Cancer Res (2012) 0.98
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer (2012) 0.95
Maraba virus as a potent oncolytic vaccine vector. Mol Ther (2013) 0.92
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther (2011) 0.92
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses (2015) 0.92
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res (2014) 0.91
Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol (2012) 0.90
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer (2013) 0.90
Live viruses to treat cancer. J R Soc Med (2013) 0.89
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res (2014) 0.87
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther (2015) 0.87
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther (2014) 0.87
Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci (2016) 0.86
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Adv Virol (2011) 0.85
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther (2015) 0.83
Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol (2016) 0.82
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther (2010) 0.82
Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One (2012) 0.81
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther (2016) 0.80
Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells. J Virol (2015) 0.79
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Reovirus in cancer therapy: an evidence-based review. Oncolytic Virother (2014) 0.78
Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants. Viruses (2015) 0.78
The hitchhiker's guide to virotherapy. Oncotarget (2012) 0.77
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther (2010) 0.76
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer (2015) 0.76
Cytotoxic effect of a combination of bluetongue virus and radiation on prostate cancer. Exp Ther Med (2014) 0.75
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Seroepidemiology of reovirus in healthy dogs in six prefectures in Japan. J Vet Med Sci (2013) 0.75
Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1. mSphere (2016) 0.75
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75
Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo. Front Oncol (2016) 0.75
Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus. PLoS One (2017) 0.75
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Mol Ther Oncolytics (2017) 0.75
Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia (2005) 5.47
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry (1995) 3.65
Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Am J Clin Pathol (1996) 3.52
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med (1993) 3.37
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol (2013) 2.41
Aortic morphology following endovascular repair of acute and chronic type B aortic dissection: implications for management. Eur J Vasc Endovasc Surg (2008) 2.32
Funduscopy: a forgotten art? Postgrad Med J (1999) 2.28
First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception (1997) 2.27
SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood (1989) 2.17
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med (1998) 2.12
Oral candidiasis. Postgrad Med J (2002) 2.02
Common region on chromosome 14 in T-cell leukemia and lymphoma. Science (1984) 1.98
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol (1992) 1.97
Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol (1990) 1.94
Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol (1999) 1.93
Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS (1992) 1.93
ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Immunity (2001) 1.92
Induction of the prospective neural crest of Xenopus. Development (1995) 1.91
Subcutaneous continuous glucose monitoring: feasibility of a new microdialysis-based glucose sensor system. Diabetes Care (2001) 1.79
Assessment of cellular telephone and other radio frequency exposure for epidemiologic research. Epidemiology (1996) 1.78
Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med (2015) 1.75
Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) (2008) 1.74
A regional psychiatric rehabilitation hospital. Br J Psychiatry (1965) 1.70
Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab (2007) 1.67
The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia (2012) 1.61
Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology (1999) 1.60
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol (1999) 1.60
Cognition in early human immunodeficiency virus infection. Arch Neurol (1990) 1.59
A novel insulin formulation with a more rapid onset of action. Diabetologia (2008) 1.57
Oral glucose tolerance test and HbA₁c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia (2011) 1.55
Vagus nerve stimulation for complex partial seizures: surgical technique, safety, and efficacy. J Neurosurg (1993) 1.55
Otological toxicity after postoperative radiotherapy for parotid tumours. Clin Oncol (R Coll Radiol) (2007) 1.49
Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev (2005) 1.48
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev (2010) 1.46
Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes Obes Metab (2012) 1.45
An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed (1993) 1.45
Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch Neurol (1992) 1.45
Hospital doctors' assessment of baseline spirometry. Postgrad Med J (1998) 1.44
Gene transfer therapy in cancer. Br J Surg (1993) 1.43
No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet Med (2002) 1.42
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 1.41
Cognition and immune function in HIV-1 infection. AIDS (1992) 1.41
Massive pulmonary emboli associated with olanzapine. Ir Med J (2008) 1.41
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
Risk factors for pneumothorax during percutaneous Hickman line insertion in patients with solid and haematological tumours. Clin Oncol (R Coll Radiol) (1995) 1.39
Air bubbles in insulin pens. Lancet (1989) 1.39
Trisomy 14: a new entity within acute nonlymphocytic leukemia. Cancer Genet Cytogenet (1989) 1.39
Radiographic guided epidural placement. Anaesthesia (2003) 1.39
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Does the chronic psychiatric patient understand plain English? Br J Psychiatry (1972) 1.38
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer (2009) 1.36
Mechanisms of global support and posttraumatic enophthalmos: I. The anatomy of the ligament sling and its relation to intramuscular cone orbital fat. Plast Reconstr Surg (1986) 1.36
Nature of the genetic determinant controlling encapsulation in Staphylococcus aureus Smith. Infect Immun (1977) 1.35
Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature (1987) 1.35
Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology (1992) 1.34
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Telomeric structure in cells with chromosome end associations. Chromosoma (1993) 1.34
Evidence of genetic resistance of cattle to infection with Mycobacterium bovis. J Dairy Sci (2010) 1.32
Polynucleotide synthesis and the genetic code. Cold Spring Harb Symp Quant Biol (1966) 1.31
Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev (2008) 1.30
Definitive radiotherapy for extramedullary plasmacytomas of the head and neck. Br J Radiol (2003) 1.29
Long-term growth of malignant thymocytes in vitro. Blood (1989) 1.28
Universal vs. risk factor-based screening for gestational diabetes mellitus: detection rates, gestation at diagnosis and outcome. Diabet Med (2000) 1.27
Cancer in blacks, whites and Asians in a British hospital. J R Coll Physicians Lond (1984) 1.27
Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol (1996) 1.26
Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab (2009) 1.26
Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia (1994) 1.25
Identifying barriers to effective tuberculosis control in Senegal: an anthropological approach. Int J Tuberc Lung Dis (2007) 1.24
The immune system--is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) (2007) 1.24
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Sensors for glucose monitoring: technical and clinical aspects. Diabetes Metab Res Rev (2001) 1.24
Prevalence of renal artery stenosis in diabetes mellitus--an autopsy study. J Intern Med (1991) 1.24
Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest (1996) 1.22
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer (2011) 1.22
Common mechanism of chromosome inversion in B- and T-cell tumors: relevance to lymphoid development. Science (1986) 1.21
Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer (2005) 1.21
Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract (1999) 1.20
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther (2005) 1.19
Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2011) 1.19
Mitochondrial gene defects in patients with NIDDM. Diabetologia (1994) 1.18